Advertisement
Organisation › Details
Innovative Medicines Initiative (IMI JU + IMI2 JU)
The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently-needed new treatments in diverse areas. IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI 2 programme, IMI has a budget of €3.3 billion for the period 2014-2020. Half of this comes from the EU’s research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects ‘in kind’, for example by donating their researchers’ time or providing access to research facilities or resources. *
Start | 2018-01-01 start | |
End | 2021-11-30 renamed | |
Group | Innovative Health Initiative (IHI JU) | |
Today | Innovative Health Initiative (IHI JU) | |
Successor | Innovative Health Initiative (IHI JU) | |
Industry | pharmaceutical | |
Industry 2 | drug discovery | |
Person | Meulien, Pierre (Innovative Medicines Initiative 201807 Executive Director) | |
Person 2 | Laverty, Hugh (Innovative Medicines Initative 201704 Head of Scientific Operations) | |
Region | EU (European Union)_oo | |
Country | EU (European Union) | |
Street | 56–60 Avenue de la Toison d’Or | |
City | 1060 Brussels | |
Tel | +32-2-221-8181 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Innovative Medicines Initiative (IMI). (5/12/20). "Press Release: IMI Announces COVID Projects, Boosts Funding Pot to EUR 72 million". Brussels. | ||
Record changed: 2023-07-15 |
Advertisement
More documents for Innovative Health Initiative (IHI JU)
- [1] Thermosome GmbH. (6/20/23). "Press Release: Thermosome Announces Participation in IMAGIO Consortium to Improve Cancer Treatment". Munich....
- [2] Insilico Biotechnology AG. (8/24/21). "Press Release: Insilico Biotechnology AG Participates in Inno4vac, a European new public-private partnership to innovate vaccine development". Stuttgart....
- [3] Exscientia Ltd.. (8/18/20). "Press Release: Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats". Brussels....
- [4] Boehringer Ingelheim. (6/8/20). "Press Release: New Consortium EUbOPEN Will Provide Tools to Unlock Disease Biology. 66 Million Euros to Generate Open-access Chemical Tools". Frankfurt & Ingelheim....
- [5] Innovative Medicines Initiative (IMI). (5/12/20). "Press Release: IMI Announces COVID Projects, Boosts Funding Pot to EUR 72 million". Brussels....
- [6] MLM Medical Labs GmbH. (4/15/19). "Press Release: Innovative Medicines Initiative Launches Translational Safety Biomarker Pipeline Project to Enable Development and Implementation of Novel Safety Biomarkers". Mönchengladbach....
- [7] bioMérieux S.A.. (4/1/19). "Press Release: University of Antwerp, bioMérieux, and Wellcome Trust to Coordinate VALUE-Dx, a European Public-Private Partnership to Fight Antimicrobial Resistance through Diagnostics". Antwerp, London & Marcy l’Eoile....
- [8] Innovative Medicines Initiative (IMI). (1/22/19). "Press Release: Open Access Drug Development Tools Feature in New IMI Call for Proposals". Brussels....
- [9] Agena Bioscience, Inc.. (7/24/18). "Press Release: Agena Announces MassARRAY Technology Selected for Participation in CANCER-ID Consortium". San Diego, CA....
- [10] Innovative Medicines Initiative (IMI). (7/18/18). "Press Release: New Antimicrobial Resistance Accelerator Programme Part of Latest IMI Calls for Proposals". Brussels....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top